{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-146179","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.249715+00:00","generated_at":"2026-05-18T19:30:09.455852+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Q32 Bio CMO resigns; appoints Adrien Sipos as Interim CMO","bullets":["Jason Campagna, M.D., Ph.D. resigns as Chief Medical Officer, effective July 9, 2025.","Adrien Sipos, M.D., Ph.D. appointed Interim CMO, effective July 9, 2025; over 25 years I&I experience.","Dr. Sipos to lead advancement of bempikibart in SIGNAL-AA Phase 2a trial for alopecia areata.","Topline results from Part B of SIGNAL-AA expected in first half of 2026.","Prior roles include Biogen, Sanofi Genzyme, Eli Lilly, and President/CMO at PRAXICO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-146179","json":"https://secwatch.observer/filing/0001193125-25-146179.json","markdown":"https://secwatch.observer/filing/0001193125-25-146179.md","text":"https://secwatch.observer/filing/0001193125-25-146179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525146179/0001193125-25-146179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525146179/d917821d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T19:30:09.455852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}